Seek Returns

PCVX vs. VTRS: Vaxcyte vs. Viatris Stock Comparison

How do Vaxcyte (PCVX) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Vaxcyte (PCVX) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Viatris (VTRS) has more than two decades of public-market history since March 17, 1980, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Vaxcyte (PCVX) and Viatris (VTRS)
Profile ItemPCVXVTRS
NameVaxcyte Inc.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization10.11 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 12, 2020March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

PCVX
VTRS
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Vaxcyte (PCVX) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Vaxcyte (PCVX) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Total Return (1Y)59.00%108.98%
Total Return (3Y, Annualized)11.29%36.75%
Total Return (5Y, Annualized)21.60%11.59%

Risk Profile

Drawdown History

PCVX
VTRS
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Vaxcyte (PCVX) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Volatility (1Y, Annualized)56.01%32.53%
Beta (5Y)1.260.86
Max Drawdown (5Y)-76.22%-45.69%
Avg. Volume (3M)2.12M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
PCVX and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Sharpe Ratio (1Y)0.983.22
Sortino Ratio (1Y)1.765.63

Profitability

ROE (TTM)

Both Vaxcyte (PCVX) at -42.68% and Viatris (VTRS) at -4.21% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Vaxcyte (PCVX) at 0.00% and Viatris (VTRS) at 13.85% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
ROE (TTM)-42.68%-4.21%
ROA (TTM)-24.98%2.91%
Net Margin (TTM)0.00%-4.13%
Operating Margin (TTM)0.00%13.85%
Gross Margin (TTM)0.00%41.13%

Growth

Revenue Growth

Only one side can be read here: Viatris (VTRS) reports revenue growth of -2.98%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Vaxcyte (PCVX) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Revenue Growth (YoY)---2.98%
Revenue Growth (3Y CAGR)---4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Current Ratio (MRQ)4.561.55
Debt / Equity (MRQ)0.090.99
Net Debt / EBITDA--2.64

Dividends

Dividend Yield (TTM)

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Vaxcyte (PCVX) pays no dividend (payout 0.00%).

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

Neither Vaxcyte (PCVX) nor Viatris (VTRS) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Viatris (VTRS), whose P/S ratio of 1.55 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): PCVX does not report P/S ratio, so it has no value marker; VTRS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Vaxcyte (PCVX) at 3.83 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Vaxcyte (PCVX) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Vaxcyte (PCVX) and Viatris (VTRS)
MetricPCVXVTRS
P/E Ratio (TTM)----
P/S Ratio (TTM)--1.55
P/B Ratio (MRQ)3.831.67
Free Cash Flow Yield (TTM)-5.24%13.84%